Select Page

EVQLV Joins Endless Frontier Labs Incubator

Sep 21, 2020 | News | 0 comments


NEW YORK, September 21, 2020 — EVQLV has been invited to join the Life Science Track of the prestigious Endless Frontier Labs (EFL) incubator. The nine-month program runs each year from October through May. The program provides:

  • Guidance from industry executives to help entrepreneurs land strategic partnerships, gain regulatory approval, and/or acquire customers

  • Scientific and operational mentorships with leaders who have taken companies through successful exits to provide companies with advice regarding high-level business development and R&D strategy

  • Input from vertical-specific investors who give critical advice from a “smart money” perspective

About Endless Frontier Labs

Founded at NYU Stern School of Business and located in New York City, Endless Frontier Labs (EFL) is at the intersection of world-renowned research and the most dynamic and innovative city in the world. EFL is a structured mentoring program that provides founders with resources, support and advice to optimize their chances for success. According to EFL’s founding director, Professor Deepak Hegde, “Our mission is to bridge the gap between science and societal impact. We believe business strategy, validation by scientific peers, and connections to investors are essential for the successful commercialization of scientific breakthroughs. To that end, EFL provides founders access to an unparalleled network of business coaches, scientists, investors, and Stern MBA students to help transform their ideas into high-growth businesses.”


‘Life Science Leader’ publishes EVQLV CEO’s Guide for “Demystifying AI”

Examining AI as automated, assistive, analytical, accelerated, or augmented intelligence is a framework for thinking about how to apply these tools to data in ways that are aligned with an organization’s goals. This framework is designed to allow those who do not routinely build or employ AI to avoid the overhyped rhetoric of AI and consider the practical outcomes of employing it.

EVQLV, Manhattan BioSolutions Announce UB CAT Grant Award

University at Buffalo Center for Advanced Technology in Big Data and Health Sciences New York City, New York Jun 29, 2021 (  - EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, and...

NY Bio-Computation Startup EVQLV Closes Financing Round

NEW YORK, February 8, 2021 -- EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, today announced the closing of a funding round that will be used to advance the company’s R&D efforts, boost development...

EVQLV Welcomes Operations & Finance Lead Alexander Sonneborn

NEW YORK, February 1, 2021 -- EVQLV is pleased to announce that Alexander Sonneborn has joined EVQLV to oversee company operations and finances. After an early career in the life sciences, Alexander transitioned to entrepreneurial activities in technology-based...

EVQLV Submits 1 Million Ab Initio Derived Sequences for Validation

NEW YORK, January 12, 2021 - EVQLV has submitted one million AI-generated sequences for independent laboratory validation in fulfillment of the second phase of a project with its collaborator. The first phase of the project consisted of 100 antibody sequences based...